BREJCHA, Martin, Martina STOKLASOVÁ, Yvona BRYCHTOVÁ, Anna PANOVSKÁ, Kristina ŠTĚPANOVSKÁ, Gabriela VAŇKOVÁ, Karla PLEVOVÁ, Alexandra OLTOVÁ, Kateřina HORKÁ, Šárka POSPÍŠILOVÁ, Jiří MAYER and Michael DOUBEK. Clonal evolution in chronic lymphocytic leukemia detected by fluorescence in situ hybridization and conventional cytogenetics after stimulation with CpG oligonucleotides and interleukin-2: A prospective analysis. Leukemia Research. Oxford: Pergamon Elsevier, 2014, vol. 38, No 2, p. 170-175. ISSN 0145-2126. doi:10.1016/j.leukres.2013.10.019.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Clonal evolution in chronic lymphocytic leukemia detected by fluorescence in situ hybridization and conventional cytogenetics after stimulation with CpG oligonucleotides and interleukin-2: A prospective analysis.
Authors BREJCHA, Martin (203 Czech Republic), Martina STOKLASOVÁ (203 Czech Republic), Yvona BRYCHTOVÁ (203 Czech Republic, belonging to the institution), Anna PANOVSKÁ (203 Czech Republic, belonging to the institution), Kristina ŠTĚPANOVSKÁ (203 Czech Republic, belonging to the institution), Gabriela VAŇKOVÁ (203 Czech Republic, belonging to the institution), Karla PLEVOVÁ (203 Czech Republic, belonging to the institution), Alexandra OLTOVÁ (203 Czech Republic, belonging to the institution), Kateřina HORKÁ (203 Czech Republic), Šárka POSPÍŠILOVÁ (203 Czech Republic, guarantor, belonging to the institution), Jiří MAYER (203 Czech Republic, belonging to the institution) and Michael DOUBEK (203 Czech Republic, belonging to the institution).
Edition Leukemia Research, Oxford, Pergamon Elsevier, 2014, 0145-2126.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30200 3.2 Clinical medicine
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 2.351
RIV identification code RIV/00216224:14740/14:00074868
Organization unit Central European Institute of Technology
Doi http://dx.doi.org/10.1016/j.leukres.2013.10.019
UT WoS 000329971200007
Keywords in English Chronic lymphocytic leukemia; Clonal evolution; CpG oligonucleotides; Cytogenetics; Fluorescence in situ hybridization; Interleukin-2
Tags EL OK, kontrola MP, podil, rivok
Tags International impact, Reviewed
Changed by Changed by: Martina Prášilová, učo 342282. Changed: 28. 4. 2015 11:03.
Abstract
Chronic lymphocytic leukemia (CLL) patients may acquire new chromosome abnormalities during the course of their disease. Clonal evolution (CE) has been detected by conventional chromosome banding (CBA), several groups also confirmed CE with fluorescence in situ hybridization (FISH). At present, there are minimal prospective data on CE frequency determined using a combination of both methods. Therefore, the aim of our study was to prospectively assess CE frequency using a combination of FISH and CBA after stimulation with CpG oligonucleotides and interleukin-2. Between 2008 and 2012, we enrolled 140 patients with previously untreated CLL in a prospective trial evaluating CE using FISH and CBA after stimulation. Patients provided baseline and regular follow-up peripheral blood samples for testing. There was a median of 3 cytogenetic examinations (using both methods) per patient. CE was detected in 15.7% (22/140) of patients using FISH, in 28.6% (40/140) using CBA, and in 34.3% (48/140) of patients by combining both methods. Poor-prognosis CE (new deletion 17p, new deletion 11q or new complex karyotype) was detected in 15% (21/140) of patients and was significantly associated with previous CLL treatment (p=0.013). CBA provides more complex information about cytogenetic abnormalities in CLL patients than FISH and confirms that many patients can acquire new abnormalities during the course of their disease in a relatively short time period.
Links
ED1.1.00/02.0068, research and development projectName: CEITEC - central european institute of technology
EE2.3.20.0045, research and development projectName: Podpora profesního růstu a mezinárodní integrace výzkumných týmů v oblasti molekulární medicíny
MSM0021622430, plan (intention)Name: Funkční a molekulární charakteristiky nádorových a normálních kmenových buněk - identifikace cílů pro nová terapeutika a terapeutické strategie
Investor: Ministry of Education, Youth and Sports of the CR, Functional and molecular characteristics of cancer and normal stem cells - identification of targets for novel therapeutics and therapeutic strategies
MUNI/A/0723/2012, interní kód MUName: Nové klinické a diagnostické přístupy u hematogických malignit (Acronym: NoKliDiPřiHeMa)
Investor: Masaryk University, Category A
NT13493, research and development projectName: Molekulární charakterizace B buněčných receptorů a jejich vztah k evoluci genetických změn u chronické lymfocytární leukémie
7E13008, research and development projectName: Next Generation Sequencing Platform for Targeted Personalized Therapy of Leukemia (Acronym: NGS-PTL)
Investor: Ministry of Education, Youth and Sports of the CR
PrintDisplayed: 26. 6. 2022 09:59